Chromocell Therapeutics Total Assets

The latest total assets for CHRO is $150M as of March 2026. That compares with $910K in the prior-year period — up 15854.9% year over year. Investors often review this figure alongside Chromocell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CHRO's total assets moved from $910K to $150M — a 15854.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Chromocell Therapeutics's operating scale or balance-sheet position.

A total assets figure of $150M for CHRO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CHRO's total assets ($150M), review year-over-year change from $910K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.